Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Arch Intern Med ; 171(3): 249-56, 2011 Feb 14.
Artículo en Inglés | MEDLINE | ID: mdl-20937917

RESUMEN

BACKGROUND: It is unclear whether lack of follow-up after screening fecal occult blood testing (FOBT) in older adults is due to screening patients whose comorbidity or preferences do not permit follow-up vs failure to complete follow-up in healthy patients. METHODS: A prospective cohort study of 2410 patients 70 years or older screened with FOBT was conducted at 4 Veteran Affairs (VA) medical centers from January 1 to December 31, 2001. The main outcome measure was receipt of follow-up within 1 year of FOBT based on national VA and Medicare data. For patients with positive FOBT results, age and Charlson comorbidity scores were evaluated as potential predictors of receiving a complete colon evaluation (colonoscopy or sigmoidoscopy plus barium enema), and medical records were reviewed to determine reasons for lack of follow-up. RESULTS: A total of 212 patients (9%) had positive FOBT results; 42% received a complete colon evaluation within 1 year. Age and comorbidity were not associated with receipt of a complete follow-up, which was similar among patients 70 to 74 years old with a Charlson score of 0 compared with patients 80 years or older with a Charlson score of 1 or higher (48% vs 41%; P=.28). The VA site, number of positive FOBT cards, and number of VA outpatient visits were predictors. Of 122 patients who did not receive a complete follow-up within 1 year, 38% had documentation that comorbidity or preferences did not permit follow-up, and over the next 5 years 76% never received a complete follow-up. CONCLUSIONS: While follow-up after positive FOBT results was low regardless of age or comorbidity, screening patients in whom complete evaluation would not be pursued substantially contributes to lack of follow-up. Efforts to improve follow-up should address the full chain of decision making, including decisions to screen and decisions to follow up.


Asunto(s)
Neoplasias Colorrectales/prevención & control , Tamizaje Masivo/estadística & datos numéricos , Sangre Oculta , Derivación y Consulta/estadística & datos numéricos , Veteranos/estadística & datos numéricos , Anciano , Anciano de 80 o más Años , Sulfato de Bario , Estudios de Cohortes , Colonoscopía/estadística & datos numéricos , Neoplasias Colorrectales/epidemiología , Comorbilidad , Medios de Contraste , Enema/estadística & datos numéricos , Femenino , Estudios de Seguimiento , Hospitales de Veteranos/estadística & datos numéricos , Humanos , Masculino , Medicare , Estudios Prospectivos , Sigmoidoscopía/estadística & datos numéricos , Negativa del Paciente al Tratamiento/estadística & datos numéricos , Estados Unidos
2.
Ann Intern Med ; 150(7): 465-73, 2009 Apr 07.
Artículo en Inglés | MEDLINE | ID: mdl-19349631

RESUMEN

BACKGROUND: The Veterans Health Administration, the American Cancer Society, and the American Geriatrics Society recommend colorectal cancer screening for older adults unless they are unlikely to live 5 years or have significant comorbidity that would preclude treatment. OBJECTIVE: To determine whether colorectal cancer screening is targeted to healthy older patients and is avoided in older patients with severe comorbidity who have life expectancies of 5 years or less. DESIGN: Cohort study. SETTING: Veterans Affairs (VA) medical centers in Minneapolis, Minnesota; Durham, North Carolina; Portland, Oregon; and West Los Angeles, California, with linked national VA and Medicare administrative claims. PATIENTS: 27 068 patients 70 years or older who had an outpatient visit at 1 of 4 VA medical centers in 2001 or 2002 and were due for screening. MEASUREMENTS: The main outcome was receipt of fecal occult blood testing (FOBT), colonoscopy, sigmoidoscopy, or barium enema in 2001 or 2002, on the basis of national VA and Medicare claims. Charlson-Deyo comorbidity scores at the start of 2001 were used to stratify patients into 3 groups ranging from no comorbidity (score of 0) to severe comorbidity (score > or =4), and 5-year mortality was determined for each group. RESULTS: 46% of patients were screened from 2001 through 2002. Only 47% of patients with no comorbidity were screened despite having life expectancies greater than 5 years (5-year mortality, 19%). Although the incidence of screening decreased with age and worsening comorbidity, it was still 41% for patients with severe comorbidity who had life expectancies less than 5 years (5-year mortality, 55%). The number of VA outpatient visits predicted screening independent of comorbidity, such that patients with severe comorbidity and 4 or more visits had screening rates similar to or higher than those of healthier patients with fewer visits. LIMITATIONS: Some tests may have been performed for nonscreening reasons. The generalizability of findings to persons who do not use the VA system is uncertain. CONCLUSION: Advancing age was inversely associated with colorectal cancer screening, whereas comorbidity was a weaker predictor. More attention to comorbidity is needed to better target screening to older patients with substantial life expectancies and avoid screening older patients with limited life expectancies. primary funding source: VA Health Services Research and Development.


Asunto(s)
Neoplasias Colorrectales/epidemiología , Tamizaje Masivo/estadística & datos numéricos , Veteranos , Factores de Edad , Anciano , Anciano de 80 o más Años , Estudios de Cohortes , Colonoscopía , Neoplasias Colorrectales/diagnóstico , Comorbilidad , Detección Precoz del Cáncer , Femenino , Humanos , Masculino , Tamizaje Masivo/métodos , Medicare , Guías de Práctica Clínica como Asunto , Estados Unidos/epidemiología , United States Department of Veterans Affairs
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA